7/102 sources · 2 publishersUpdated Nov 16, 22:55 UTC
Acrivon Therapeutics posts Q3 loss, cash runway to Q4 2027 and GAAP EPS beat
Acrivon Therapeutics reported a net loss of $17.9 million for Q3 2026, slightly better than the $18.2 million loss a year earlier. The company held $77.8 million in cash and investments, which it expects to fund operations into Q4 2027. GAAP earnings per share were –$0.42, beating consensus by $0.02. The stock slipped 2.05% in after‑hours trading.
Why it matters
The cash balance gives the firm liquidity through the next fiscal year, reducing short‑term financing risk. The EPS beat shows marginally better profitability than analysts expected, though the share price fell, indicating market concern despite the beat.
Key facts
- 1Net loss for Q3 2026 was $17.9 million. tradingview.com
- 2Net loss for Q3 2025 was $18.2 million. tradingview.com
- 3Cash and investments as of September 30 2026 totaled $77.8 million. tradingview.com
- 4The cash balance is expected to last into Q4 2027. tradingview.com
- 5GAAP EPS for Q3 2026 was –$0.42, beating estimates by $0.02. seekingalpha.com
- 6Shares fell 2.05% in after‑hours trading following the release. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.